An non-curated DGI for FGFR3 and ponatinib was called on the results of the study “Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models” by Gozgit et al.12. Here, MTOR is linked to endometrial cancer.